In vitro Evaluation of Biofield Treatment on Viral Load Against Human Immunodeficiency-1 and Cytomegalo Viruses
American Journal of Health Research
Volume 3, Issue 6, November 2015, Pages: 338-343
Received: Oct. 9, 2015; Accepted: Oct. 19, 2015; Published: Nov. 16, 2015
Views 5432      Downloads 144
Authors
Mahendra Kumar Trivedi, Trivedi Global Inc., Henderson, USA
Alice Branton, Trivedi Global Inc., Henderson, USA
Dahryn Trivedi, Trivedi Global Inc., Henderson, USA
Gopal Nayak, Trivedi Global Inc., Henderson, USA
Sambhu Charan Mondal, Trivedi Science Research Laboratory Pvt. Ltd., Bhopal, Madhya Pradesh, India
Snehasis Jana, Trivedi Science Research Laboratory Pvt. Ltd., Bhopal, Madhya Pradesh, India
Article Tools
Follow on us
Abstract
Viral load quantification is the amount of particular viral DNA or RNA in a blood samples. It is one of the surrogate biomarker of AIDS. High viral load indicates that the immune system is failed to fight against viruses. The aim of this study was to evaluate the impact of biofield treatment on HIV-1 and HCMV in terms of viral loads as surrogate marker. The viral load assay was performed on stored stock cultures of HIV infected human plasma samples before and after 7 days of biofield treatment using Roche COBAS® AMPLICOR analyzer. Viral load (HIV-1 RNA and HCMV DNAaemia) was considered as surrogate marker for assessment of the impact of Mr. Trivedi’s biofield treatment in HIV infected stored plasma samples. The viral load quantification of HIV-1 RNA in infected stored plasma samples was significantly reduced by 65% in biofield treated group as compared to control. Additionally, viral load of HCMV DNAaemia in infected stored plasma samples was also reduced by 80% in the biofield treated group as compared to control. Because, children are more prone to HCMV infection and adults are generally liable to suffer from HIV-1 infection. As the biofield treatment has reduced HCMV DNAaemia, it could be beneficial for HIV infected children populations. Altogether, data suggest that biofield treatment has significantly reduced the viral load quantification in HIV-1 and HCMV infected stored plasma samples and could be a suitable alternative treatment strategy for AIDS patients in near future.
Keywords
Human Immune Deficiency Virus, Biofield Treatment, Cytomegalo Virus, Viral Load, HIV RNA, HCMV DNAaemia, AIDS, Surrogate Biomarker
To cite this article
Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana, In vitro Evaluation of Biofield Treatment on Viral Load Against Human Immunodeficiency-1 and Cytomegalo Viruses, American Journal of Health Research. Vol. 3, No. 6, 2015, pp. 338-343. doi: 10.11648/j.ajhr.20150306.14
Copyright
Copyright © 2015 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Buonaguro L, Tornesello ML, Buonaguro FM (2007) Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: Pathogenetic and therapeutic implications. J Virol 81: 10209-10219.
[2]
Janeway CA (2001) Immunobiology: The immune system in health and disease. (5thedn), New York, Garland Science.
[3]
Kassutto S, Rosenberg ES (2004) Primary HIV type 1 infection. Clin Infect Dis 38: 1447-1453.
[4]
Chakravarti A, Kashyap B, Matlani M (2009) Cytomegalovirus infection: An Indian perspective. Indian J Med Microbiol 27: 3-11.
[5]
Eshraghi H, Hekmat R (2015) Which CMV viral load threshold should be defined as CMV infection in kidney transplant patients? Transplant Proc 47: 1136-1139.
[6]
Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, et al. (1996) Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272: 1167-1170.
[7]
Obrien WA, Hartigan PM, Martin D, Esinhart J, Hill A, et al. (1996) Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans affairs cooperative study group on AIDS. N Engl J Med 334: 426-431.
[8]
Spector SA, Merrill R, Wolf D, Daukner WM (1992) Detection of human cytomegalovirus in plasma of AIDS patients during acute visceral disease by DNA amplification. J Clin Microbiol 30: 2359-2365.
[9]
Palumbo PE, Kwok S, Waters S, Wesley Y, Lewis D, et al. (1995) Viral measurement by polymerase chain reaction-based assays in human immunodeficiency virus-infected infants. J Pediatr 126: 592-595.
[10]
McIntosh K, Shevitz A, Zaknun D, Kornegay J, Chatis P, et al. (1996) Age and time-related changes in extracellular viral load in children infected with human immunodeficiency virus. Pediatr Infect Dis J 15: 1087-1091.
[11]
Boriskin Y, Sharland M, Dalton R, duMont G, Booth J, et al. (1999) Viral loads in dual infection with HIV-1 and cytomegalovirus. Arch Dis Child 80: 132-136.
[12]
Lane HC (1989) The role of immunomodulators in the treatment of patients with AIDS. AIDS 3: S181-S185.
[13]
Trivedi MK, Tallapragada RM, Branton A, Trivedi D, Nayak G, et al. (2015) Characterization of physical, spectral and thermal properties of biofield treated 1,2,4-Triazole. J Mol Pharm Org Process Res 3: 128.
[14]
Shinde V, Sances F, Patil S, Spence A (2012) Impact of biofield treatment on growth and yield of lettuce and tomato. Aust J Basic Appl Sci 6: 100-105.
[15]
Sances F, Flora E, Patil S, Spence A, Shinde V (2013) Impact of biofield treatment on ginseng and organic blueberry yield. Agrivita J Agric Sci 35.
[16]
Nayak G, Altekar N (2015) Effect of biofield treatment on plant growth and adaptation. J Environ Health Sci 1: 1-9.
[17]
Berger A, Scherzed L, Sturmer M, Preiser W, Doerr HW, et al. (2002) Evaluation of the Cobas AmpliPrep/Cobas Amplicor HIV-1 Monitor Ultrasensitive Test: Comparison with the Cobas Amplicor HIV-1 Monitor test (manual specimen preparation). J Clin Virol 25: S103-S107.
[18]
Irene GS, Jennie AW, Mark JE, Carlos VP (2000) Thomas FS evaluation of the COBAS AMPLICOR CMV MONITOR Test for detection of viral DNA in specimens taken from patients after liver transplantation. J Clin Microbiol 38: 600-606.
[19]
Murray JS, Elashoff MR, Iacono-Connors LC, Cvetkovich TA, Struble KA (1999) The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS. 13: 797-804.
[20]
Ernst E (1997) Complementary AIDS therapies: The good, the bad and the ugly. Int J STD AIDS 8: 281-285.
[21]
Kirksey KM, Goodroad BK, Kemppainen JK, Holzemer LW, Bunch EH, et al. (2002) Complementary therapy use in persons with HIV/AIDS. J Holist Nurs 20: 264-278.
[22]
Bowen EF, Wilson P, Cope A, Sabin C, Griffiths P, et al. (1996) Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival. AIDS 10: 1515-1520.
[23]
Spector SA, Wong R, Hsia K, Pilcher M, Stempien MJ (1998) Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J Clin Invest 101: 497-502.
[24]
Yu ZG, Song X (2001) Variable range hopping and electrical conductivity along the DNA double helix. Phys Rev Lett 86: 6018.
[25]
Tran P, Alavi B, Grunen G (2000) Charge transport along the lambda DNA double helix. Phys Rev Lett 85: 1564-1567.
[26]
Marshall RJ The best kept secret in nutrition: The body’s biofield communication system. Premier research labs. Austin, TX 78667.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186